180 related articles for article (PubMed ID: 32606935)
1. Comprehensive Analysis of PD-1 Gene Expression, Immune Characteristics and Prognostic Significance in 1396 Glioma Patients.
Liu C; Zhang Z; Ping Y; Qin G; Zhang K; Maimela NR; Huang L; Yang S; Zhang Y
Cancer Manag Res; 2020; 12():4399-4410. PubMed ID: 32606935
[TBL] [Abstract][Full Text] [Related]
2. Large-scale analysis reveals the specific clinical and immune features of B7-H3 in glioma.
Zhang C; Zhang Z; Li F; Shen Z; Qiao Y; Li L; Liu S; Song M; Zhao X; Ren F; He Q; Yang B; Fan R; Zhang Y
Oncoimmunology; 2018; 7(11):e1461304. PubMed ID: 30377558
[No Abstract] [Full Text] [Related]
3. CD96, a new immune checkpoint, correlates with immune profile and clinical outcome of glioma.
Liu F; Huang J; He F; Ma X; Fan F; Meng M; Zhuo Y; Zhang L
Sci Rep; 2020 Jul; 10(1):10768. PubMed ID: 32612110
[TBL] [Abstract][Full Text] [Related]
4. Molecular and clinical characterization of CD163 expression via large-scale analysis in glioma.
Liu S; Zhang C; Maimela NR; Yang L; Zhang Z; Ping Y; Huang L; Zhang Y
Oncoimmunology; 2019; 8(7):1601478. PubMed ID: 31143523
[TBL] [Abstract][Full Text] [Related]
5. Immune and Clinical Features of
Zhang Q; Zhong H; Fan Y; Liu Q; Song J; Yao S; Cao F
Front Bioeng Biotechnol; 2020; 8():592. PubMed ID: 32695752
[TBL] [Abstract][Full Text] [Related]
6. Identification of the novel prognostic biomarker, MLLT11, reveals its relationship with immune checkpoint markers in glioma.
Chen L; Xiong Z; Zhao H; Teng C; Liu H; Huang Q; Wanggou S; Li X
Front Oncol; 2022; 12():889351. PubMed ID: 36033495
[TBL] [Abstract][Full Text] [Related]
7. Molecular and clinical characterization of TIM-3 in glioma through 1,024 samples.
Li G; Wang Z; Zhang C; Liu X; Cai J; Wang Z; Hu H; Wu F; Bao Z; Liu Y; Zhao L; Liang T; Yang F; Huang R; Zhang W; Jiang T
Oncoimmunology; 2017; 6(8):e1328339. PubMed ID: 28919992
[No Abstract] [Full Text] [Related]
8. Interferon gamma-related gene signature based on anti-tumor immunity predicts glioma patient prognosis.
Zhang Z; Shen X; Tan Z; Mei Y; Lu T; Ji Y; Cheng S; Xu Y; Wang Z; Liu X; He W; Chen Z; Chen S; Lv Q
Front Genet; 2022; 13():1053263. PubMed ID: 36712869
[No Abstract] [Full Text] [Related]
9. Characterization of transcriptome profile and clinical features of a novel immunotherapy target CD204 in diffuse glioma.
Yuan Y; Zhao Q; Zhao S; Zhang P; Zhao H; Li Z; Du Y; Tian X; Lu J
Cancer Med; 2019 Jul; 8(8):3811-3821. PubMed ID: 31140757
[TBL] [Abstract][Full Text] [Related]
10. PD-1 related transcriptome profile and clinical outcome in diffuse gliomas.
Liu S; Wang Z; Wang Y; Fan X; Zhang C; Ma W; Qiu X; Jiang T
Oncoimmunology; 2018; 7(2):e1382792. PubMed ID: 29308304
[No Abstract] [Full Text] [Related]
11. Transcriptome profile and clinical characterization of ICOS expression in gliomas.
Wang J; Shi F; Shan A
Front Oncol; 2022; 12():946967. PubMed ID: 36276141
[TBL] [Abstract][Full Text] [Related]
12. Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma.
Wang Z; Zhang C; Liu X; Wang Z; Sun L; Li G; Liang J; Hu H; Liu Y; Zhang W; Jiang T
Oncoimmunology; 2016; 5(11):e1196310. PubMed ID: 27999734
[No Abstract] [Full Text] [Related]
13. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
14. PD-L2 expression is correlated with the molecular and clinical features of glioma, and acts as an unfavorable prognostic factor.
Wang ZL; Li GZ; Wang QW; Bao ZS; Wang Z; Zhang CB; Jiang T
Oncoimmunology; 2019; 8(2):e1541535. PubMed ID: 30713802
[No Abstract] [Full Text] [Related]
15. CD44-Mediated Poor Prognosis in Glioma Is Associated With M2-Polarization of Tumor-Associated Macrophages and Immunosuppression.
Xiao Y; Yang K; Wang Z; Zhao M; Deng Y; Ji W; Zou Y; Qian C; Liu Y; Xiao H; Liu H
Front Surg; 2021; 8():775194. PubMed ID: 35187044
[TBL] [Abstract][Full Text] [Related]
16. Molecular and clinical characterization of PTPN2 expression from RNA-seq data of 996 brain gliomas.
Wang PF; Cai HQ; Zhang CB; Li YM; Liu X; Wan JH; Jiang T; Li SW; Yan CX
J Neuroinflammation; 2018 May; 15(1):145. PubMed ID: 29764444
[TBL] [Abstract][Full Text] [Related]
17. Large-Scale Analysis Reveals the Specific Clinical and Immune Features of DGCR5 in Glioma.
Wu X; Hou P; Qiu Y; Wang Q; Lu X
Onco Targets Ther; 2020; 13():7531-7543. PubMed ID: 32801772
[TBL] [Abstract][Full Text] [Related]
18. Clinical characterization and immunosuppressive regulation of CD161 (KLRB1) in glioma through 916 samples.
Di W; Fan W; Wu F; Shi Z; Wang Z; Yu M; Zhai Y; Chang Y; Pan C; Li G; Kahlert UD; Zhang W
Cancer Sci; 2022 Feb; 113(2):756-769. PubMed ID: 34881489
[TBL] [Abstract][Full Text] [Related]
19. Stanniocalcin 1 is a prognostic biomarker in glioma.
Luo W; Chen D; Wang H; Hu J
Oncol Lett; 2020 Sep; 20(3):2248-2256. PubMed ID: 32782542
[TBL] [Abstract][Full Text] [Related]
20. Prognostic role of mitochondrial pyruvate carrier in isocitrate dehydrogenase-mutant glioma.
Karsy M; Guan J; Huang LE
J Neurosurg; 2018 Mar; 130(1):56-66. PubMed ID: 29547090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]